Phytochemical Name : Paclitaxel

Properties Information
PhytoCAT-ID PhytoCAT-164
Phytochemical name or plant extracts Paclitaxel
PMID 7669713
Literature evidence Paclitaxel was administered by 3-hour intravenous infusion every three weeks in all patients, and if possible, all were evaluated neurologically before paclitaxel, after every other cycle and after discontinuation of therapy.
IUPAC name [(1S,2S,3R,4S,7R,9S,10S,12R,15S)-4,12-diacetyloxy-15-[(2R,3S)-3-benzamido-2-hydroxy-3-phenylpropanoyl]oxy-1,9-dihydroxy-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.03,10.04,7]heptadec-13-en-2-yl] benzoate
Phytochemicals’ class or type of plant extracts Diterpenoid
Source of phytochemicals or plant Extracts Taxus brevifolia
Geographical availability Alaska, Alberta, British Columbia, California, Idaho, Montana, Oregon, Washington
Plant parts Bark
Other cancers Ovarian cancer, Breast cancer, Lung cancer, Head and neck cancer
Target gene or protein EF1a ,FOXO3a, Bcl-2
Gene or Protein evidence Paclitaxel increased the phosphorylation of AMPK and also downregulated the expression of EF1α in MCF7 cells. Paclitaxel suppresses the viability of breast tumor MCF7 cells through the regulation of EF1α and FOXO3a by AMPK signaling.
Target pathways AMPK/EF1α/FOXO3a signaling pathway
IC50 33.7 ± 4.2 nM against MCF-7
Potency Paclitaxel is a plant taxane mitotic inhibitor approved for primary or salvage treatment of ovarian and breast cancer.
Cell line/ mice model MCF-7
Additional information  Paclitaxel is more likely to be associated with peripheral neuropathy and myalgias/arthralgias than docetaxel.
PubChem ID 36314
Additional PMIDs 33357719 7908664 7551941 10344150 26179168 7619331 15907983 26397839 21796250 24152585 25981924 26124351 9891802 15846465 7610396 17152485 17152485 18985033 18668363 23844611 25442283 27056899 28314310 30849160 31708973 33823894 34280009 7910054
Additional sources of information https://powo.science.kew.org/taxon/urn:lsid:ipni.org:names:249736-2
Safety NA